CAR-T Meeting 2024 | A summary of the prognostic factors that can influence the outcomes of anti-CD19 CAR-T in R/R DLBCL
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, provides an overview of the prognostic factors that can influence the outcomes of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Prior to infusion, critical prognostic factors include age, comorbidities, performance status, and disease characteristics (lactate dehydrogenase level, total metabolic tumor burden, levels of inflammatory markers). Different CAR-T products vary in efficacy and cellular composition, impacting patient outcomes. In the post-infusion setting, the early disease response and measurable residual disease (MRD) status predict the long-term outcomes of the therapy. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria.
